CytomX Therapeutics Inc
CTMX
Get informed when a big investor buys or sells
+ FollowMarket Cap$578.96M
Close$
$6.51
102.3% upside
Current Fair Value
102.3% upsideUndervalued by 102.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $578.96 Million |
|---|---|
| Enterprise Value | $570.87 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.15 |
| Beta | 2.17 |
| Outstanding Shares | 177,273,000 |
Return
| Return on Equity | -18.48% |
|---|---|
| Return on Assets | -16.46% |
| Return on Invested Capital | -19.87% |
Valuation & Multiples
| P/E Ratio | -10.79 |
|---|---|
| PEG | 6.08 |
| Price to Sales | - |
| Price to Book Ratio | 3.22 |
| Enterprise Value to Revenue | 16.06 |
| Enterprise Value to EBIT | -8.83 |
| Enterprise Value to Net Income | -10 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.06 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 11, 2026
EPS Estimate
$-0.14
Average shareholder expectationRevenue Estimate
$4.68 M
Average shareholder expectationNext Earnings Call
Expected Date
August 6, 2026
EPS Estimate
$-0.11
Average shareholder expectationRevenue Estimate
$11.19 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.6740▲ 61.80% |
|---|---|
| Total Calls | 2,599,301▲ 102.44% |
| Total Puts | 1,751,800▲ 2339.83% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 140.04%▲ 52.74% |
|---|---|
| Total Invested | $907.86M▲ 47.93% |
| Investors Holding | 191▲ 61.00% |
ESG Score
No data
About CytomX Therapeutics Inc
CEO: Sean McCarthy